Neurizons, NUZ-001

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk

Neurizon Therapeutics Limited Australia New York

View original content:https://www.prnewswire.co.uk/news-releases/neurizons-nuz-001-reduces-aggregation-of-key-als-disease-target-tdp-43-in-preclinical-study-302309581.html

en | US87612E1064 | NEURIZONS | boerse | 67934042 |